Semax vs Selank: The Nootropic Peptides Your Psychiatrist Doesn't Know About

The Russian Peptide Pharmacy Backstory

If you discovered Semax and Selank through a biohacking forum or a nootropics subreddit, you probably encountered the same cognitive dissonance: these are described as approved pharmaceutical drugs — yet your physician has never heard of them, and they are not available at any Western pharmacy.

That dissonance has a specific historical explanation.

Both peptides were developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow. Research began in earnest in the 1970s and 80s, when Soviet neuroscience was operating with significant autonomy from Western scientific publishing norms. The Cold War created parallel research traditions: Soviet neurochemists were investigating peptide fragments derived from known hormones, and their results were being published in Russian-language journals largely invisible to Western researchers.

The key figure in Semax's development is Nikolai Myasoedov and colleagues at the Institute of Molecular Genetics. Selank was developed by the same institution and the V.V. Zakusov Research Institute of Pharmacology. Both peptides entered Russian clinical use in the 1990s and 2000s after passing the Soviet and then Russian pharmaceutical approval process — a process that, while real, does not meet the same standards as FDA Phase I/II/III trials.

This context matters when you read the evidence section. "Approved drug with clinical data" sounds rigorous until you understand that the approval pathway involved trials published primarily in Russian journals, conducted by the same institutional groups that developed the compounds, without the independent replication that characterizes Western drug approval. It is more evidence than a typical peptide like BPC-157 has — but less than a peer-reviewed, multicenter, placebo-controlled trial published in a high-impact English-language journal.

Today, Semax and Selank are primarily sourced from Russian online pharmacies or domestic research chemical vendors, which adds further complexity around quality control and authenticity.

How Semax Works: ACTH, BDNF, and the Focus Circuit

Semax is a synthetic heptapeptide — a seven-amino-acid chain with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was designed as a stable analog of ACTH(4-10), a fragment of adrenocorticotropic hormone (ACTH).

ACTH is the pituitary hormone that signals the adrenal glands to produce cortisol. But ACTH(4-10) is a fragment that retains ACTH's neurological effects — neuroprotection, attention modulation, memory consolidation — while lacking its cortisol-stimulating activity. This separation is important: Semax can produce ACTH-like cognitive effects without elevating cortisol, which would produce stress and immunosuppression.

Primary Mechanisms

• BDNF upregulation: Semax's most studied and consistently replicated effect is a significant increase in brain-derived neurotrophic factor (BDNF) in cortical and hippocampal tissue. This is relevant to learning, memory consolidation, and neuroplasticity. Animal studies show increases of 1.4–2x in BDNF expression following Semax administration.
• NGF upregulation: Alongside BDNF, Semax increases nerve growth factor (NGF), supporting peripheral and central neuron maintenance — particularly in the cholinergic system relevant to memory and attention.
• Dopaminergic and serotonergic modulation: Semax influences dopamine metabolism in the striatum and frontal cortex, which correlates with improved motivation and executive function. It also modulates serotonin systems, contributing to the mood-brightening effect many users describe.
• Melanocortin receptor activity: As an ACTH analog, Semax interacts with melanocortin receptors (MC1R–MC5R), which regulate inflammatory response, energy, and neurotransmitter balance. MC4R involvement in particular has been linked to attention and cognitive processing.
• Anti-inflammatory neuroprotection: Semax reduces neuroinflammatory markers following ischemic injury in animal models, which is the basis for its clinical use in stroke rehabilitation in Russia.

Administration and Pharmacokinetics

Semax is administered intranasally as a 0.1% solution. Intranasal delivery bypasses the blood-brain barrier via olfactory transport, which explains the rapid onset. Onset is typically reported at 30–60 minutes, with peak effects around 1–2 hours. Duration of cognitive effect is 4–8 hours, with some neuroprotective effects that may persist longer due to BDNF's longer half-life as a signaling molecule.

Typical research doses range from 200–900 mcg intranasal per administration, divided across 1–3 daily doses. The Russian pharmaceutical formulation is 0.1% drops, with standard dosing at 3 drops per nostril (approximately 300 mcg total per dose).

How Selank Works: Tuftsin, GABA, and the Anxiety Circuit

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It is a stabilized analog of tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) produced by the spleen with known immunomodulatory properties. The Pro-Gly-Pro extension added by researchers at the Institute of Molecular Genetics dramatically increased its metabolic stability, allowing it to cross the blood-brain barrier and persist long enough to produce neurological effects.

While Semax was designed primarily for cognitive enhancement and neuroprotection, Selank was developed with anxiety and stress as the primary targets. Its therapeutic approval in Russia is specifically for generalized anxiety disorder (GAD), neurasthenia, and psycho-vegetative syndrome — conditions characterized by diffuse anxiety, fatigue, and stress intolerance.

Primary Mechanisms

• GABA-A receptor potentiation: Selank's anxiolytic effect appears to involve positive modulation of GABA-A receptors, the same receptor complex targeted by benzodiazepines. However, unlike benzodiazepines, Selank appears to modulate GABA-A in a more selective, dose-dependent fashion — producing anxiolysis without the muscle relaxation, sedation, or respiratory depression that characterize benzo use. Crucially, no physical dependence or tolerance development has been observed in animal models or clinical observations.
• Serotonin and norepinephrine modulation: Selank increases serotonin turnover and modulates norepinephrine release in brain regions associated with stress response. This may explain the mood-stabilizing effect independent of pure GABAergic activity.
• BDNF upregulation: Like Semax, Selank increases BDNF expression — though the magnitude appears smaller in direct comparison studies. The BDNF effect provides a cognitive-preserving component alongside the anxiolytic action, which is part of why Selank doesn't simply sedate.
• IL-6 modulation: Selank significantly reduces IL-6 (interleukin-6), a pro-inflammatory cytokine that is elevated in chronic stress, depression, and anxiety disorders. The neuroinflammatory pathway is increasingly recognized as central to mood disorders, and Selank's IL-6 effects represent a mechanistically credible anti-anxiety action beyond pure neurotransmitter modulation.
• Enkephalin stability: Some research suggests Selank stabilizes enkephalins (endogenous opioid peptides involved in stress response and mood regulation) by inhibiting their enzymatic degradation — a mechanism potentially relevant to emotional resilience under stress.

Administration and Pharmacokinetics

Selank is administered intranasally as a 0.15% solution. Onset is typically reported at 15–30 minutes — faster than Semax, which aligns with its more acute anxiolytic profile. Duration is 4–6 hours. Typical doses range from 250–3000 mcg per administration, with the Russian pharmaceutical standard at approximately 250–750 mcg per dose (3 drops per nostril of 0.15% solution).

The BDNF Connection: What Both Peptides Share

Brain-derived neurotrophic factor (BDNF) is one of the most studied molecules in neuroscience, and for good reason. It is the primary driver of neuroplasticity — the brain's ability to form new synaptic connections, consolidate memories, and adapt to new information. Low BDNF is associated with depression, anxiety, cognitive decline, and neurodegenerative diseases. High BDNF is associated with learning, resilience, and cognitive performance.

The fact that both Semax and Selank independently increase BDNF — through different receptor systems and by different magnitudes — is not a coincidence. It reflects a convergent design principle: both were developed to improve brain function under stress or pathology, and BDNF is one of the most direct markers of neurological health.

Semax vs Selank on BDNF

In animal studies, Semax produces a larger BDNF increase than Selank — sometimes 2x or more above baseline in cortical and hippocampal tissue. This is consistent with Semax's stronger cognitive-stimulating profile. Selank's BDNF upregulation is more modest but still meaningful, particularly in the context of chronic stress where BDNF is typically suppressed.

For practical purposes: if BDNF optimization is the goal (for neuroprotection, cognitive performance, or neuroplasticity), Semax is the more potent choice. Selank's BDNF effects are a meaningful secondary benefit rather than its primary value proposition.

Head-to-Head Comparison: Onset, Duration, Effects, Side Effects

Who Each One Is Best For

Despite their shared Russian origin and overlapping BDNF effects, Semax and Selank serve meaningfully different primary use cases. Here's how to think about which one — or which combination — fits your situation.

It is worth noting that brain fog has different root causes, and the correct peptide depends on which one is driving the fog. Semax is better for fog caused by low dopamine drive, cognitive fatigue, or lack of mental engagement. Selank is better for fog caused by anxiety, cortisol overload, or hypervigilance that crowds out focus. Many people have both components simultaneously — which is why the stack exists.

Stacking Protocols for Brain Fog

The Semax + Selank combination is the canonical nootropic peptide stack in Russian medicine and in Western self-experimentation communities. Their complementary mechanisms create a well-reasoned rationale for combined use.

The Classic Semax + Selank Stack

Rationale: Semax provides cognitive drive via BDNF/ACTH-like mechanisms and dopaminergic activation. Selank provides the anxiety floor — preventing the stimulant edge from becoming anxiety-driven cognitive fragmentation. Together they address both under-activation and over-activation of the stress response system.

Common protocol:

• Morning: Semax 300–600 mcg intranasal (for focus and drive)
• Afternoon or as needed: Selank 250–750 mcg intranasal (for anxiety management or to extend productive state without stimulant overhang)

Some users take both peptides simultaneously in the morning for the combined calming-yet-focused effect. Others prefer temporal separation to preserve Semax's stimulating lift in the morning and use Selank as a second-stage wind-down without sedation.

Stack Considerations by Brain Fog Type

• Brain fog with anxiety: Start with Selank alone. If focus remains impaired after anxiety resolves, add Semax.
• Brain fog without anxiety (flat, unmotivated, low drive): Start with Semax. Add Selank only if stimulant effects feel edgy.
• Burnout presentation (exhausted, wired, can't focus): Start with Selank to restore baseline. Introduce Semax later when the system is less reactive.
• Performance/productivity context (deadline, exam, presentation): The combined stack on the day of is a common approach for experienced users.

Cycling

There is no established clinical protocol for cycling either peptide. Community convention is to use Semax and Selank on a 5 days on, 2 days off schedule or to cycle with 2–4 week breaks to prevent any habituation of downstream receptor systems. There are no peer-reviewed studies establishing an optimal cycling protocol in healthy humans.

Honest Evidence Tiers

One of the distinguishing features of Semax and Selank compared to most nootropic peptides discussed in Western biohacking communities is that they have actual clinical trial data — not just animal studies. But that data comes with significant caveats.

Where this leaves us: Semax and Selank occupy a tier above typical research peptides (like BPC-157 or TB-500 in their current state) and below FDA/EMA-approved drugs. They are regionally approved drugs with a clinical evidence base — but that base has not been independently validated by Western-standard trials. The honest position is promising, plausible, and used by informed adults — not proven by gold-standard evidence.

vs. SSRIs, Benzos & Modafinil: An Honest Comparison

This is the comparison most people are actually interested in when they reach this article. Here is a direct, unsanitized assessment.

Semax vs Modafinil

Modafinil is FDA-approved for narcolepsy and shift work disorder, and widely used off-label for cognitive enhancement and wakefulness. It has a well-characterized mechanism (primarily orexin system / histamine pathway, indirect dopamine effects) and extensive safety data. Semax is not FDA-approved and has far less safety data in healthy Western adults.

That said, users who have tried both frequently note:

• Semax has a cleaner focus profile with less edge, less jaw tension, and no cardiovascular acceleration
• Semax produces a more mood-positive effect — modafinil can feel sterile or emotionally flat
• Semax doesn't appear to disrupt sleep as severely as modafinil if used in the morning
• Modafinil has far more human safety data and a defined pharmacological profile in humans

Bottom line: For users who want a focus tool and find modafinil too harsh, Semax is a plausible alternative — but with less evidence. They are not equivalent in terms of regulatory status or clinical validation.

Selank vs Benzodiazepines

This comparison is where Selank's profile becomes most compelling. Benzodiazepines (Xanax, Valium, Klonopin) are the standard pharmacological tool for acute anxiety — they work quickly and powerfully by broadly potentiating GABA-A receptors. They also carry well-documented downsides: physical dependence within weeks, tolerance requiring dose escalation, cognitive impairment, withdrawal syndromes that can be medically dangerous, and abuse potential.

Selank's GABA-A activity appears to be more selective and partial — producing anxiolysis at lower receptor efficacy, which may explain the lack of observed tolerance or dependence. There are no head-to-head clinical trials comparing Selank to standard benzodiazepines in Western populations, but the mechanistic distinction is real and meaningful.

Important caveat: Selank is not a replacement for benzodiazepines in someone with severe anxiety, panic disorder, or who is already dependent on benzos. Anyone managing a diagnosed anxiety disorder with prescription medication should not substitute Selank without physician guidance.

Semax and Selank vs SSRIs

The comparison to SSRIs is the trickiest. SSRIs are first-line treatment for depression and anxiety with decades of clinical data and well-characterized effects. They are not perfect drugs — the side effect profile (weight, sex drive, emotional blunting) is real — but they represent a rigorously studied intervention for conditions that can be seriously disabling.

Semax and Selank are not alternatives to SSRIs for clinical depression or anxiety disorders. What they offer is a faster-onset, potentially cleaner-feeling, non-pharmaceutical option for people whose cognitive and emotional challenges fall short of clinical diagnosis — or as adjuncts for people who want to complement pharmaceutical treatment. The absence of long-term human safety data is a genuine gap that informed users should weigh honestly.

Frequently Asked Questions

What is the difference between Semax and Selank?

Semax is primarily a cognitive enhancer — it boosts focus, mental clarity, and BDNF while providing mild stimulation. Selank is primarily anxiolytic — it reduces anxiety with a calm, clear-headed effect, no sedation, and no observed dependence. Both are Russian-developed synthetic heptapeptides with shared BDNF-upregulating properties. They are often used together for combined cognitive and anxiety management.

Is Semax or Selank better for brain fog?

It depends on what's causing the fog. If the fog is driven by low motivation, poor focus, or cognitive fatigue — Semax. If the fog is driven by anxiety, stress, or cortisol overload — Selank. For the common mixed presentation (both anxious and unfocused), the Semax + Selank stack addresses both vectors simultaneously.

Are Semax and Selank legal in the US?

Neither is FDA-approved and neither is a scheduled controlled substance in the US. They exist in a regulatory gray zone — legal to possess for personal use in most US states, but not approved for therapeutic use and not commercially available through licensed pharmacies. Legal status varies by country. Always verify local regulations.

Can you stack Semax and Selank?

Yes. It's one of the most common peptide stack protocols. Semax in the morning for cognitive drive, Selank as needed for anxiety management or calm focus. No known pharmacological interactions, though formal research on the combination is not available.

How do Semax and Selank compare to SSRIs?

They are not comparables in the clinical sense. SSRIs are FDA-approved, rigorously studied, and work over weeks. Semax and Selank act within hours, are not FDA-approved, and have limited Western clinical data. They are not replacements for prescribed psychiatric medications. Consult a physician before combining with any psychiatric drug.